Overview SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures Status: RECRUITING Trial end date: 2027-12-31 Target enrollment: Participant gender: Summary This is a Phase 3 open-label extension study to evaluate the long-term safety and efficacy of SPN-817.Phase: PHASE3 Details Lead Sponsor: Supernus Pharmaceuticals, Inc.